Trial Profile

A Phase Ib/II, Open Label, Proof-of-concept Study of Sabatolimab and Magrolimab-based Therapy for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Magrolimab (Primary) ; Sabatolimab (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

09 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
02 Sep 2022 Planned End Date changed from 20 Jul 2027 to 26 Oct 2029.
02 Sep 2022 Planned primary completion date changed from 20 Jul 2027 to 26 Oct 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com